Inhaled drug developer Transpire Bio has announced the hires of Timothy Lutz as VP of Manufacturing and Operations; Stuart Loesch as Chief Commercial Officer; and Todd Sunstrom as Head of Quality Assurance. The company recently announced the initiation of a Phase 1 trial for a generic inhaler for asthma and COPD. Last October, Transpire officially opened its new headquarters and manufacturing facility in Florida.
All three of the new hires have extensive experience in pharmaceuticals. Lutz was most recently Senior VP of Manufacturing Operations at ProKidney and was previously Chief Manufacturing Officer at Matica Biotechnology. His previous experience also includes stints at Lonza, PharmaForce, and Discovery Labs. Loesch was most recently President and Chief Commercial Officer of Intrommune Therapeutics and previously served in marketing roles at numerous companies, including Meda, Merck, Teva, and GSK. Sunstrom was most recently VP for Quality Assurance at Syncromune and was previously Associate VP for Quality Assurance & Regulatory Affairs at Goodwin Biotechnology.
Transpire Bio CEO Xian-Ming Zeng commented, “With the recent expansion of our research and manufacturing capabilities, it is the perfect time to bring additional expertise to our leadership team in the critical areas of commercialization, quality assurance, and manufacturing. Stuart, Todd, and Tim are all accomplished leaders in the pharmaceutical industry, and I am excited to welcome them to the Transpire Bio team. Their contributions will be invaluable as we continue to advance our pipeline of innovative inhaled therapeutics for pulmonary and systemic diseases with high unmet medical needs.”
Read the Transpire Bio press release.
